viewpointImmunological/physiological relationships in asthma: potential regulation by lung macrophages
References (31)
- et al.
J. Allergy Clin. Immunol.
(1981) - et al.
New Engl. J. Med.
(1992) - et al.
Clin. exp. Allergy
(1992) Eur. Respir. J. Suppl.
(1991)- et al.
J. Immunol.
(1990) - et al.
Eur. Respir. J. Suppl.
(1991) - et al.
Eur. Respir. J.
(1990) J. Clin. Path.
(1960)- et al.
Am. Rev. Respir. Dis.
(1985)
Thorax
Eosinophils
J. Pathol.
Respiration
Thorax
Cited by (68)
The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
2010, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Potential effects of roflumilast N-oxide or roflumilast on alveolar macrophages from patients with COPD or on other functions besides LPS-induced TNF-α release remain to be explored. However, the apparently small effect of the PDE4 inhibitors on macrophages may not necessarily be a disadvantage, given the occurrence of a population of immunosuppressive macrophages [136] and the critical role ascribed to macrophages in innate defence and phagocytosis of apoptotic neutrophils, an important step in inflammation resolution. After transendothelial migration to the airway lumen, neutrophils cross the interstitial space along the surface of lung fibroblasts (presumably supported by sensing of fibroblast intercellular adhesion molecule-1 [ICAM-1] by neutrophil CD11b/CD18) before contacting the epithelial basement membrane [137].
Molecular mechanisms in allergy and clinical immunology: Antigen-presenting cells in allergy
2001, Journal of Allergy and Clinical Immunology'Anergic' T cells modulate the T-cell activating of antigen-presenting cells
2000, Journal of AutoimmunityCharacterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
1999, Pulmonary Pharmacology and Therapeutics